CIPROBID 500MG TABS
₹47.60
Ciprobid 500 mg Tablet contains Ciprofloxacin, a fluoroquinolone antibiotic used to treat various bacterial infections, including those affecting the urinary tract, respiratory system, skin, and gastrointestinal tract.
Description
Ciprobid 500 mg Tablet, manufactured by Zydus Cadila, contains Ciprofloxacin 500 mg, a broad-spectrum fluoroquinolone antibiotic. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination, thereby preventing bacterial cell division and growth.
Indications:
Ciprobid 500 mg Tablet is prescribed for the treatment of various bacterial infections, including:
-
Urinary Tract Infections (UTIs)
-
Respiratory Tract Infections (e.g., pneumonia, bronchitis)
-
Skin and Soft Tissue Infections
-
Gastrointestinal Infections (e.g., infectious diarrhea)
-
Bone and Joint Infections
-
Sexually Transmitted Infections (e.g., gonorrhea)
-
Anthrax Exposure
Dosage and Administration:
-
The dosage and duration depend on the type and severity of the infection and should be determined by a healthcare professional.
-
It can be taken with or without food, but should be taken at the same time each day.
-
Avoid taking it with dairy products or calcium-fortified juices alone, as they can interfere with absorption.
Side Effects:
Common side effects may include:
-
Nausea
-
Diarrhea
-
Headache
-
Dizziness
-
Abdominal pain
Serious side effects can include:
-
Tendonitis or tendon rupture
-
Peripheral neuropathy
-
Central nervous system effects (e.g., seizures, tremors)
-
Hypersensitivity reactions
Precautions:
-
Use with caution in patients with a history of tendon disorders, seizures, or renal impairment.
-
Not recommended during pregnancy or breastfeeding unless prescribed by a doctor.
-
Avoid excessive exposure to sunlight or UV light, as Ciprofloxacin can increase photosensitivity.
-
Inform your doctor about all other medications you are taking to avoid potential interactions.
Reviews
There are no reviews yet.